Submission
The Prix Galien Canada - Research Award will be presented to the researcher or the research team judged by the Jury to have made the most significant contribution to research in Canada.
Eligibility
The Prix Galien is open to any person or team who has been involved for at least the last five years in research leading or making a substantial contribution to the diagnosis, prevention or treatment of disease. Candidates from academia, health care institutions, research centers and industry are eligible.
Prix Galien Canada guarantees that all information will be held in strict confidentiality and will be available only to parties involved in the adjudication of the award.
Submission The submission date for the 2023 Prix Galien Research Award will be announced at a later date. |
The Prix Galien Canada - Innovative Product Award will be presented to a drug, launched at least 12 months ago and no more than 60 months (5 years) ago, that has made the most significant overall contribution to patient care in Canada, according to the Jury of Prix Galien Canada.
- The product is considered a “break-through” rather than a derivative of an already existing agent
- The product has made a most significant overall contribution to patient care in Canada in terms of efficacy, safety, benefits, and innovation
- The product has a major impact on standards of care
If applicable, the candidate will detail the Canadian contribution to the discovery and/or development of the product and to the contribution to publications related to the product.
Eligibility
- the diagnosis treatment, mitigation or prevention of a disease, a disorder, an abnormal physical state or the symptoms thereof, in humans and animals;
- restoring, correcting or modifying organic functions in humans or animals;
- disinfection in premises in which food is manufactured, prepared or kept.
For the purpose of Prix Galien Canada, the Jury will use the definition of “drug” in the Food and Drug Act. “Drug” includes any substance or mixture of substances manufactured, sold or represented for use in:
It must be stressed that to be considered, the drug product must bear a Drug Identification Number (D.I.N.)
Prix Galien Canada guarantees that all information will be held in strict confidentiality and will be available only to parties involved in the adjudication of the award.
Submission The submission date for the 2023 Prix Galien Innovative Product Award will be announced at a later date. |